{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:49:59Z","timestamp":1789418999576,"version":"build-2803163510"},"reference-count":170,"publisher":"Touch Medical Media, Ltd.","issue":"2","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"abstract":"<p\/>","DOI":"10.17925\/ee.2020.16.2.122","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T15:09:56Z","timestamp":1602688196000},"page":"122","source":"Crossref","is-referenced-by-count":12,"title":["Anticancer Medications and Sodium Dysmetabolism"],"prefix":"10.17925","volume":"16","author":[{"given":"Aishwarya","family":"Krishnamurthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Endocrinology Department, Max Super Speciality Hospital, Patparganj, New Delhi, Delhi, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarshi","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Endocrinology Department, Max Super Speciality Hospital, Patparganj, New Delhi, Delhi, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejal","family":"Lathia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Endocrinology Department, Fortis Hospital, Vashi, Navi Mumbai, Maharashtra, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viny","family":"Kantroo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Respiratory Department, Critical Care and Sleep Medicine, Apollo Hospitals, Sarita Vihar, New Delhi, Delhi, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kalra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Endocrinology Department, Bharti Hospital, Karnal, Haryana, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CEDAR Superspeciality Clinics, Dwarka, New Delhi, Delhi, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Livshits Z, Rao RB, Smith SW. An approach to chemotherapy-associated toxicity.\n                      Emerg Med Clin North Am\n                      . 2014;32:167\u2013203.","DOI":"10.1016\/j.emc.2013.09.002"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Gizowski C, Bourque CW. The neural basis of homeostatic and anticipatory thirst.\n                      Nat Rev Nephrol\n                      . 2018;14:11\u201325.","DOI":"10.1038\/nrneph.2017.149"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Knepper MA, Kwon T-H, Nielsen S. Molecular physiology of water balance.\n                      N Engl J Med\n                      . 2015;372:1349\u201358.","DOI":"10.1056\/NEJMra1404726"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ball SG. Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin.\n                      Ann Clin Biochem\n                      . 2007;44:417\u201331.","DOI":"10.1258\/000456307781646030"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies.\n                      Biomed Pharmacother\n                      . 2017;94:317\u201325.","DOI":"10.1016\/j.biopha.2017.07.091"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Fitzsimons JT. Angiotensin, thirst, and sodium appetite.\n                      Physiol Rev\n                      . 1998;78:583\u2013686.","DOI":"10.1152\/physrev.1998.78.3.583"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Stricker E, Sved A. Controls of vasopressin secretion and thirst: similarities and dissimilarities in signals.\n                      Physiol Behav\n                      . 2002;77:731\u20136.","DOI":"10.1016\/S0031-9384(02)00926-5"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Robben JH, Knoers NVAM, Deen PMT. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus.\n                      Am J Physiol-Ren Physiol\n                      . 2006;291:F257\u201370.","DOI":"10.1152\/ajprenal.00491.2005"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Baylis PH. Osmoregulation and control of vasopressin secretion in healthy humans.\n                      Am J Physiol\n                      . 1987;253:R671\u20138.","DOI":"10.1152\/ajpregu.1987.253.5.R671"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Porzionato A, Macchi V, Stecco C, De Caro R. The carotid sinus nerve-structure, function, and clinical implications.\n                      Anat Rec\n                      . 2019;302:575\u201387.","DOI":"10.1002\/ar.23829"},{"key":"ref11","unstructured":"Fahim M. Cardiovascular sensory receptors and their regulatory mechanisms.\n                      Indian J Physiol Pharmacol\n                      . 2003;47:124\u201346."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Perlewitz A, Persson AE, Patzak A. The juxtaglomerular apparatus.\n                      Acta Physiol\n                      . 2012;205:6\u20138.","DOI":"10.1111\/j.1748-1716.2012.02429.x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease.\n                      Physiol Rev\n                      . 2010;90:513\u201357.","DOI":"10.1152\/physrev.00007.2009"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Rubattu S, Sciarretta S, Valenti V, et al. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases.\n                      Am J Hypertens\n                      . 2008;21:733\u201341.","DOI":"10.1038\/ajh.2008.174"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Goldsmith SR. Vasopressin as vasopressor.\n                      Am J Med\n                      . 1987;82:1213\u20139.","DOI":"10.1016\/0002-9343(87)90228-2"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Santos RAS, Oudit GY, Verano-Braga T, et al. The renin-angiotensin system: going beyond the classical paradigms.\n                      Am J Physiol Heart Circ Physiol\n                      . 2019;316:H958\u201370.","DOI":"10.1152\/ajpheart.00723.2018"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Berghmans T, Paesmans M, Body J-J. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis.\n                      Support Care Cancer\n                      . 2000;8:192\u20137.","DOI":"10.1007\/s005200050284"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Li Y, Chen X, Shen Z, et al. Electrolyte and acid-base disorders in cancer patients and its impact on clinical outcomes: evidence from a real-world study in China.\n                      Ren Fail\n                      . 2020;42:234\u201343.","DOI":"10.1080\/0886022X.2020.1735417"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Khan MI, Dellinger RP, Waguespack SG. Electrolyte disturbances in critically ill cancer patients: an endocrine perspective.\n                      J Intensive Care Med\n                      . 2018;33:147\u201358.","DOI":"10.1177\/0885066617706650"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Salahudeen AK, Doshi SM, Shah P. The frequency, cost, and clinical outcomes of hypernatraemia in patients hospitalized to a comprehensive cancer center.\n                      Support Care Cancer\n                      . 2013;21:1871\u20138.","DOI":"10.1007\/s00520-013-1734-6"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ezoe Y, Mizusawa J, Katayama H, et al. An integrated analysis of hyponatremia in cancer patients receiving platinum-based or nonplatinum-based chemotherapy in clinical trials (JCOG1405-A).\n                      Oncotarget\n                      . 2017;9:6595\u2013606.","DOI":"10.18632\/oncotarget.23536"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Berardi R, Rinaldi S, Caramanti M, et al. Hyponatremia in cancer patients: Time for a new approach.\n                      Crit Rev Oncol Hematol\n                      . 2016;102:15\u201325.","DOI":"10.1016\/j.critrevonc.2016.03.010"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients.\n                      Oncologist\n                      . 2012;17:756\u201365.","DOI":"10.1634\/theoncologist.2011-0400"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease.\n                      J Intern Med\n                      . 1995;238:97\u2013110.","DOI":"10.1111\/j.1365-2796.1995.tb00907.x"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypernatraemia.\n                      Am J Kidney Dis\n                      . 2008;52:144\u201353.","DOI":"10.1053\/j.ajkd.2008.03.004"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Onitilo AA, Kio E, Doi SAR. Tumor-related hyponatremia.\n                      Clin Med Res\n                      . 2007;5:228\u201337.","DOI":"10.3121\/cmr.2007.762"},{"key":"ref27","unstructured":"Radulescu D, Pripon S, Bunea D, et al. Endocrine paraneoplastic syndromes in small cell lung carcinoma. Two case reports.\n                      J BUON\n                      . 2007;12:411\u20134."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Shimizu K, Nakano S, Nakano Y, et al. Ectopic atrial natriuretic peptide production in small cell lung cancer with the syndrome of inappropriate antidiuretic hormone secretion.\n                      Cancer\n                      . 1991;68:2284\u20138.","DOI":"10.1002\/1097-0142(19911115)68:10<2284::AID-CNCR2820681030>3.0.CO;2-Z"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Miljic D, Doknic M, Stojanovic M, et al. Impact of etiology, age and gender on onset and severity of hyponatremia in patients with hypopituitarism: retrospective analysis in a specialised endocrine unit.\n                      Endocrine\n                      . 2017;58:312\u20139.","DOI":"10.1007\/s12020-017-1415-1"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Yee AH, Burns JD, Wijdicks EFM. Cerebral salt wasting: pathophysiology, diagnosis, and treatment.\n                      Neurosurg Clin N Am\n                      . 2010;21:339\u201352.","DOI":"10.1016\/j.nec.2009.10.011"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Girot H, D\u00e9hais M, Fraissinet F, et al. Atypical pseudohyponatremia.\n                      Clin Chem\n                      . 2018;64:414\u20135.","DOI":"10.1373\/clinchem.2017.276501"},{"key":"ref32","unstructured":"Giri P, George J, Gupta AK, Gupta R. Pseudohyponatremia in multiple myeloma.\n                      J Assoc Physicians India\n                      . 2010;58:519\u201320."},{"key":"ref33","unstructured":"Kumar B, Singh S, Skvortsova I, Kumar V. Promising targets in anti-cancer drug development: recent updates.\n                      Curr Med Chem\n                      . 2017;24:4729\u201352."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors.\n                      Trends Pharmacol Sci\n                      . 2015;36:422\u201339.","DOI":"10.1016\/j.tips.2015.04.005"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Berghmans T. Hyponatremia related to medical anticancer treatment.\n                      Support Care Cancer\n                      . 1996;4:341\u201350.","DOI":"10.1007\/BF01788840"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients.\n                      Support Care Cancer\n                      . 2007;15:1341\u20137.","DOI":"10.1007\/s00520-007-0309-9"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Ravikumar TS, Grage TB. The syndrome of inappropriate ADH secretion secondary to vinblastine-bleomycin therapy.\n                      J Surg Oncol\n                      . 1983;24:242\u20135.","DOI":"10.1002\/jso.2930240322"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Janczar S, Zalewska-Szewczyk B, Mlynarski W. Severe hyponatremia in a single-center series of 84 homogenously treated children with acute lymphoblastic leukemia.\n                      J Pediatr Hematol Oncol\n                      . 2017;39:e54\u20138.","DOI":"10.1097\/MPH.0000000000000758"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Borker AS, Hutchins S, Grant R, et al. Syndrome of inappropriate secretion of anti-diuretic hormone in children with acute lymphoblastic leukemia.\n                      Blood\n                      . 2006;108:4474.","DOI":"10.1182\/blood.V108.11.4474.4474"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Seetharam S, Thankamony P, Gopakumar KG, Krishna KMJ. Higher incidence of syndrome of inappropriate antidiuretic hormone secretion during induction chemotherapy of acute lymphoblastic leukemia in indian children.\n                      Indian J Cancer\n                      . 2019;56:320\u20134.","DOI":"10.4103\/ijc.IJC_737_18"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Spigel DR, Hainsworth JD, Lane CM, et al. Phase II trial of vinflunine in relapsed small cell lung cancer.\n                      J Thorac Oncol\n                      . 2010;5:874\u20138.","DOI":"10.1097\/JTO.0b013e3181d86b76"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Hammond IW, Ferguson JA, Kwong K, et al. Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of vincristine: an over-representation of Asians?\n                      Pharmacoepidemiol Drug Saf\n                      . 2002;11:229\u201334.","DOI":"10.1002\/pds.695"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Moriyama B, Henning SA, Leung J, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.\n                      Mycoses\n                      . 2012;55:290\u20137.","DOI":"10.1111\/j.1439-0507.2011.02158.x"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Nagappa M, Bhat RR, Sudeep K, et al. Vincristine-induced acute life-threatening hyponatremia resulting in seizure and coma.\n                      Indian J Crit Care Med\n                      . 2009;13:167\u20138.","DOI":"10.4103\/0972-5229.58545"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Liamis G, Filippatos TD, Elisaf MS. Electrolyte disorders associated with the use of anticancer drugs.\n                      Eur J Pharmacol\n                      . 2016;777:78\u201387.","DOI":"10.1016\/j.ejphar.2016.02.064"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Suskind RM, Brusilow SW, Zehr J. Syndrome of inappropriate secretion of antidiuretic hormone produced by vincristine toxicity (with bioassay of ADH level).\n                      J Pediatr\n                      . 1972;81:90\u20132.","DOI":"10.1016\/S0022-3476(72)80381-0"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Zavagli G, Ricci G, Tataranni G, et al. Life-threatening hyponatremia caused by vinblastine.\n                      Med Oncol Tumor Pharmacother\n                      . 1988;5:67\u20139.","DOI":"10.1007\/BF03003183"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Stuart MJ, Cuaso C, Miller M, Oski FA. Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine.\n                      Blood\n                      . 1975;45:315\u201320.","DOI":"10.1182\/blood.V45.3.315.315"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Burdman JA. A note on the selective toxicity of vincristine sulfate on chick-embryo sensory ganglia in tissue culture.\n                      J Natl Cancer Inst\n                      . 1966;37:331\u20135.","DOI":"10.1093\/jnci\/37.3.331"},{"key":"ref50","unstructured":"Rufener C, Nordmann J, Rouiller C. [Effect of vincristine on the rat posterior pituitary in vitro].\n                      Neurochirurgie\n                      . 1972;18:137\u201341."},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Tomiwa K, Mikawa H, Hazama F, et al. Syndrome of inappropriate secretion of antidiuretic hormone caused by vincristine therapy: a case report of the neuropathology.\n                      J Neurol\n                      . 1983;229:267\u201372.","DOI":"10.1007\/BF00313556"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Garofeanu CG, Weir M, Rosas-Arellano MP, et al. Causes of reversible nephrogenic diabetes insipidus: a systematic review.\n                      Am J Kidney Dis\n                      . 2005;45:626\u201337.","DOI":"10.1053\/j.ajkd.2005.01.008"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Ali I, Wani WA, Saleem K, Haque A. Platinum compounds: a hope for future cancer chemotherapy.\n                      Anticancer Agents Med Chem\n                      . 2013;13:296\u2013306.","DOI":"10.2174\/1871520611313020016"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Hatakeyama S, Shida T, Yamaguchi H. Risk factors for severe hyponatremia related to cisplatin: A retrospective case-control study.\n                      Biol Pharm Bull\n                      . 2019;42:1891\u20137.","DOI":"10.1248\/bpb.b19-00477"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Arakawa Y, Tamura M, Sakuyama T, et al. Early measurement of urinary N-acetyl-\u03b2-glucosaminidase helps predict severe hyponatremia associated with cisplatin-containing chemotherapy.\n                      J Infect Chemother\n                      . 2015;21:502\u20136.","DOI":"10.1016\/j.jiac.2015.03.008"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.\n                      Lancet Oncol\n                      . 2015;16:1630\u20138.","DOI":"10.1016\/S1470-2045(15)00305-8"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer.\n                      Ann Oncol\n                      . 2015;26:141\u20138.","DOI":"10.1093\/annonc\/mdu472"},{"key":"ref58","unstructured":"Matsumura E, Oshiro Y, Miyagi R, et al. [A case of renal salt wasting syndrome progressing to severe hyponatremia after gemcitabine-cisplatin chemotherapy].\n                      Hinyokika Kiyo\n                      . 2012;58:425\u20139."},{"key":"ref59","unstructured":"Suzuki H, Hirashima T, Kobayashi M, et al. [Renal salt-wasting syndrome progressing to severe hyponatremia after chemotherapy-a case report].\n                      Gan To Kagaku Ryoho\n                      . 2010;37:543\u20136."},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Cao L, Joshi P, Sumoza D. Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report.\n                      Am J Clin Oncol\n                      . 2002;25:344\u20136.","DOI":"10.1097\/00000421-200208000-00005"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Giaccone G, Donadio M, Ferrati P, et al. Disorders of serum electrolytes and renal function in patients treated with cis-platinum on an outpatient basis.\n                      Eur J Cancer Clin Oncol\n                      . 1985;21:433\u20137.","DOI":"10.1016\/0277-5379(85)90033-1"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride.\n                      Cancer\n                      . 1977;39:1362\u201371.","DOI":"10.1002\/1097-0142(197704)39:4<1362::AID-CNCR2820390403>3.0.CO;2-N"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Hutchison FN, Perez EA, Gandara DR, et al. Renal salt wasting in patients treated with cisplatin.\n                      Ann Intern Med\n                      . 1988;108:21\u20135.","DOI":"10.7326\/0003-4819-108-1-21"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Kurtzberg J, Dennis VW, Kinney TR. Cisplatinum-induced renal salt wasting.\n                      Med Pediatr Oncol\n                      . 1984;12:150\u20134.","DOI":"10.1002\/mpo.2950120219"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Abid H, Siddiqui N, Gnanajothy R. Severe hyponatremia due to cisplatin-induced syndrome of inappropriate secretion of antidiuretic hormone.\n                      Cureus\n                      . 2019;11:e5458.","DOI":"10.7759\/cureus.5458"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Tan AC, Marx GM. Cisplatin-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) with life-threatening hyponatraemia.\n                      BMJ Case Rep\n                      . 2018;2018:bcr2017222948.","DOI":"10.1136\/bcr-2017-222948"},{"key":"ref67","unstructured":"Ohtaka M, Hattori Y, Kumano Y, et al. [Severe hyponatremia after cisplatin-based chemotherapy: two case reports].\n                      Hinyokika Kiyo\n                      . 2016;62:361\u20136."},{"key":"ref68","unstructured":"Sawano T, Kawasaki H, Wajima N, et al. [A case of syndrome of inappropriate antidiuretic hormone secretion in a patient with esophageal carcinoma possibly induced by cisplatin in neoadjuvant chemotherapy].\n                      Gan To Kagaku Ryoho\n                      . 2014;41:999\u20131003."},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Lee YK, Shin DM. Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer.\n                      Korean J Intern Med\n                      . 1992;7:118\u201321.","DOI":"10.3904\/kjim.1992.7.2.118"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Ready NE, Pang HH, Gu L, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance).\n                      J Clin Oncol\n                      . 2015;33:1660\u20135.","DOI":"10.1200\/JCO.2014.57.3105"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Khanna A. Acquired nephrogenic diabetes insipidus.\n                      Semin Nephrol\n                      . 2006;26:244\u20138.","DOI":"10.1016\/j.semnephrol.2006.03.004"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Amlal H, Krane CM, Chen Q, Soleimani M. Early polyuria and urinary concentrating defect in potassium deprivation.\n                      Am J Physiol Renal Physiol\n                      . 2000;279:F655\u201363.","DOI":"10.1152\/ajprenal.2000.279.4.F655"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Clifton K, Barnett C, Martinez A, et al. Two case reports of severe hyponatremia following cyclophosphamide infusion in breast cancer patients.\n                      Breast J\n                      . 2018;24:691\u20132.","DOI":"10.1111\/tbj.13026"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Bode U, Seif SM, Levine AS. Studies on the antidiuretic effect of cyclophosphamide: Vasopressin release and sodium excretion.\n                      Med Pediatr Oncol\n                      . 1980;8:295\u2013303.","DOI":"10.1002\/mpo.2950080312"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide.\n                      Arch Intern Med\n                      . 1985;145:548\u20139.","DOI":"10.1001\/archinte.1985.00360030196034"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Lee Y-C, Park J-S, Lee CH, et al. Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide.\n                      Nephrol Dial Transplant\n                      . 2010;25:1520\u20134.","DOI":"10.1093\/ndt\/gfp657"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Gilbar PJ, Richmond J, Wood J, Sullivan A. Syndrome of inappropriate antidiuretic hormone secretion induced by a single dose of oral cyclophosphamide.\n                      Ann Pharmacother\n                      . 2012;46:e23.","DOI":"10.1345\/aph.1R296"},{"key":"ref78","unstructured":"Bonella BM, Warley F. [Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study cyclophosphamide and hyponatremia].\n                      Rev Fac Cienc Medicas Cordoba Argent\n                      . 2017;74:201\u20136."},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Tang P, Zhang Y, Gao W, Geng C. Hyponatremia induced by low-dose cyclophosphamide in two patients with breast cancer.\n                      Breast J\n                      . 2014;20:442\u20133.","DOI":"10.1111\/tbj.12296"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Kirch C, Gachot B, Germann N, et al. Recurrent ifosfamide-induced hyponatraemia.\n                      Eur J Cancer\n                      . 1997;33:2438\u20139.","DOI":"10.1016\/S0959-8049(97)00329-8"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Tsutsumi Y, Shiratori S, Nakata A, et al. Hyponatremia after administration of conditioning regimen in myelodysplastic syndrome with empty sella after glandula pituitaria surgery.\n                      Ann Hematol\n                      . 2007;86:843\u20134.","DOI":"10.1007\/s00277-007-0291-9"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Shimizu T, Okamoto I, Tamura K, et al. Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.\n                      Cancer Chemother Pharmacol\n                      . 2009;65:243\u201350.","DOI":"10.1007\/s00280-009-1028-3"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Glezerman IG. Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis.\n                      Ann Oncol\n                      . 2009;20:1283\u20135.","DOI":"10.1093\/annonc\/mdp312"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Greenbaum-Lefkoe B, Rosenstock JG, Belasco JB. Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan.\n                      Cancer\n                      . 1985;55:44\u20136.","DOI":"10.1002\/1097-0142(19850101)55:1<44::AID-CNCR2820550107>3.0.CO;2-B"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Larose P, Ong H, du Souich P. The effect of cyclophosphamide on arginine vasopressin and the atrial natriuretic factor.\n                      Biochem Biophys Res Commun\n                      . 1987;143:140\u20134.","DOI":"10.1016\/0006-291X(87)90641-3"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Campbell DM, Atkinson A, Gillis D, Sochett EB. Cyclophosphamide and water retention: mechanism revisited.\n                      J Pediatr Endocrinol Metab\n                      . 2000;13:673\u20135.","DOI":"10.1515\/JPEM.2000.13.6.673"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Misharin AV, Resnenko AB, Fidelina OV, et al. Antidiuretic hormone-V2-receptor-aquaporin-2 system in rat kidneys during acute inflammation.\n                      Bull Exp Biol Med\n                      . 2004;138:452\u20136.","DOI":"10.1007\/s10517-005-0068-x"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"H\u00f6cherl K, Schmidt C, Kurt B, Bucher M. Inhibition of NF-kappaB ameliorates sepsis-induced downregulation of aquaporin-2\/V2 receptor expression and acute renal failure in vivo.\n                      Am J Physiol Renal Physiol\n                      . 2010;298:F196\u2013204.","DOI":"10.1152\/ajprenal.90607.2008"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Park SJ, Kim JH, Shin JI. Insight on mechanism of hyponatraemia induced by low-dose intravenous pulse cyclophosphamide.\n                      Nephrol Dial Transplant\n                      . 2010;25:3453;author reply 3453\u20134.","DOI":"10.1093\/ndt\/gfq429"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"McBride WH, Hoon DB, Jung T, et al. Cyclophosphamide-induced alterations in human monocyte functions.\n                      J Leukoc Biol\n                      . 1987;42:659\u201366.","DOI":"10.1002\/jlb.42.6.659"},{"key":"ref91","unstructured":"Finn G, Denning D. Transient nephrogenic diabetes insipidus following high-dose cyclophosphamide chemotherapy and autologous bone marrow transplantation.\n                      Cancer Treat Rep\n                      . 1987;71:220\u20131."},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Derman B, Jain M, McAninch E, Gashti C. Bendamustine-induced nephrogenic diabetes insipidus.\n                      Clin Nephrol\n                      . 2017;87:47\u201350.","DOI":"10.5414\/CN108908"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.\n                      Immunol Cell Biol\n                      . 2018;96:21\u201333.","DOI":"10.1111\/imcb.1003"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations.\n                      Front Oncol\n                      . 2018;8:86.","DOI":"10.3389\/fonc.2018.00086"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors.\n                      J Clin Endocrinol Metab\n                      . 2013;98:1361\u201375.","DOI":"10.1210\/jc.2012-4075"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"de Filette J, Andreescu CE, Cools F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors.\n                      Horm Metab Res\n                      . 2019;51:145\u201356.","DOI":"10.1055\/a-0843-3366"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.\n                      J Clin Endocrinol Metab\n                      . 2014;99:4078\u201385.","DOI":"10.1210\/jc.2014-2306"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Saito T, Ishikawa S-E, Ando F, et al. Vasopressin-dependent upregulation of aquaporin-2 gene expression in glucocorticoid-deficient rats.\n                      Am J Physiol Ren Physiol\n                      . 2000;279:F502\u20138.","DOI":"10.1152\/ajprenal.2000.279.3.F502"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Zhao C, Tella SH, Del Rivero J, et al. Anti-PD-L1 treatment induced central diabetes insipidus.\n                      J Clin Endocrinol Metab\n                      . 2018;103:365\u20139.","DOI":"10.1210\/jc.2017-01905"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.\n                      Endocr Relat Cancer\n                      . 2014;21:371\u201381.","DOI":"10.1530\/ERC-13-0499"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms.\n                      J Clin Endocrinol Metab\n                      . 2017;102:2770\u201380.","DOI":"10.1210\/jc.2017-00448"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.\n                      Ann Oncol\n                      . 2017;28:583\u20139.","DOI":"10.1093\/annonc\/mdw640"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Liamis G, Filippatos TD, Liontos A, Elisaf MS. Management of endocrine disease: hypothyroidism-associated hyponatremia: mechanisms, implications and treatment.\n                      Eur J Endocrinol\n                      . 2017;176:R15\u201320.","DOI":"10.1530\/EJE-16-0493"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Ohara M, Cadnapaphornchai MA, Summer SN, et al. Effect of mineralocorticoid deficiency on ion and urea transporters and aquaporin water channels in the rat.\n                      Biochem Biophys Res Commun\n                      . 2002;299:285\u201390.","DOI":"10.1016\/S0006-291X(02)02634-7"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Arlt W, Allolio B. Adrenal insufficiency.\n                      Lancet Lond Engl\n                      . 2003;361:1881\u201393.","DOI":"10.1016\/S0140-6736(03)13492-7"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Martinelli E, De Palma R, Orditura M, et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.\n                      Clin Exp Immunol\n                      . 2009;158:1\u20139.","DOI":"10.1111\/j.1365-2249.2009.03992.x"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Jhaveri KD, Sakhiya V, Wanchoo R, et al. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System.\n                      Kidney Int\n                      . 2016;90:706\u20137.","DOI":"10.1016\/j.kint.2016.06.027"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Kunz JS, Bannerji R. Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone.\n                      Leuk Lymphoma\n                      . 2005;46:635\u20137.","DOI":"10.1080\/10428190400029858"},{"key":"ref109","unstructured":"Yasuhara H, Imagawa A, Koike N, et al. [A case of renal salt-wasting syndrome during chemotherapy for advanced gastric cancer].\n                      Gan To Kagaku Ryoho\n                      . 2015;42:225\u20137."},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Turner N, Stewart J, Barnett F, White S. Syndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancer.\n                      Asia Pac J Clin Oncol\n                      . 2012;8:e9\u201311.","DOI":"10.1111\/j.1743-7563.2012.01526.x"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Wedam S, Fashoyin-Aje L, Gao X, et al. FDA approval summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer.\n                      Clin Cancer Res\n                      . 2020;26:4180\u20135.","DOI":"10.1158\/1078-0432.CCR-19-3980"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Kolarich AR, Reynolds BA, Heldermon CD. Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage.\n                      Acta Oncol\n                      . 2014;53:1434\u20136.","DOI":"10.3109\/0284186X.2014.920959"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rck E, Samuelsson J. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) after treatment with cyclophosphamide, \u03b1-interferon and betamethasone in a patient with multiple myeloma.\n                      Eur J Haematol\n                      . 1996;56:323\u20135.","DOI":"10.1111\/j.1600-0609.1996.tb00724.x"},{"key":"ref114","unstructured":"Mastorakos G, Weber JS, Magiakou MA, et al. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion.\n                      J Clin Endocrinol Metab\n                      . 1994;79:934\u20139."},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.\n                      Leuk Lymphoma\n                      . 2013;54:683\u20137.","DOI":"10.3109\/10428194.2012.728597"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management.\n                      Nephrol Dial Transplant\n                      . 2006;21:70\u20136.","DOI":"10.1093\/ndt\/gfi082"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.\n                      Br J Haematol\n                      . 2014;165:375\u201381.","DOI":"10.1111\/bjh.12755"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.\n                      Leukemia\n                      . 2013;27:1902\u20139.","DOI":"10.1038\/leu.2013.95"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Gupta S, Seethapathy H, Strohbehn IA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma.\n                      Am J Kidney Dis\n                      . 2020;76:63\u201371.","DOI":"10.1053\/j.ajkd.2019.10.011"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Dixon BN, Daley RJ, Buie LW, et al. Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells.\n                      Clin Nephrol\n                      . 2020;93:42\u20136.","DOI":"10.5414\/CN109872"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Jhaveri KD, Wanchoo R, Sakhiya V, et al. Adverse renal effects of novel molecular oncologic targeted therapies: A narrative review.\n                      Kidney Int Rep\n                      . 2017;2:108\u201323.","DOI":"10.1016\/j.ekir.2016.09.055"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Biswas B, Ghadyalpatil N, Krishna M, Deshmukh J. A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.\n                      Indian J Cancer\n                      . 2017;54(Suppl.):S55\u201364.","DOI":"10.4103\/ijc.IJC_589_17"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Lalami Y, Garcia C, Flamen P, et al. Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and\/or metastatic head and neck cancer: Outcome in patients with recurrent and\/or metastatic head and neck cancer.\n                      Head Neck\n                      . 2016;38:347\u201354.","DOI":"10.1002\/hed.23898"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"Llovet JM, Decaens T, Raoul J-L, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.\n                      J Clin Oncol\n                      . 2013;31:3509\u201316.","DOI":"10.1200\/JCO.2012.47.3009"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Johnson PJ, Qin S, Park J-W, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.\n                      J Clin Oncol\n                      . 2013;31:3517\u201324.","DOI":"10.1200\/JCO.2012.48.4410"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Huang J, Meng L, Yang B, et al. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting system.\n                      Sci Rep\n                      . 2020;10:4803.","DOI":"10.1038\/s41598-020-61571-5"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Khaja M, Torchon F, Millerman K. A rare case of sorafenib-induced severe hyponatremia.\n                      SAGE Open Med Case Rep\n                      . 2019;7:2050313X1984604.","DOI":"10.1177\/2050313X19846048"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Liapis K, Apostolidis J, Charitaki E, et al. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.\n                      Ann Pharmacother\n                      . 2008;42:1882\u20136.","DOI":"10.1345\/aph.1L410"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"Hill J, Shields J, Passero V. Tyrosine kinase inhibitor-associated syndrome of inappropriate secretion of anti-diuretic hormone.\n                      J Oncol Pharm Pract\n                      . 2016;22:729\u201332.","DOI":"10.1177\/1078155215592023"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"Laplante M, Sabatini DM. mTOR signaling at a glance.\n                      J Cell Sci\n                      . 2009;122:3589\u201394.","DOI":"10.1242\/jcs.051011"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy.\n                      Int J Mol Sci\n                      . 2019;20:755.","DOI":"10.3390\/ijms20030755"},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors.\n                      Transplant Rev (Orlando)\n                      . 2014;28:126\u201333.","DOI":"10.1016\/j.trre.2014.03.002"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"Guo J, Huang Y, Zhang X, et al. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.\n                      BMC Cancer\n                      . 2013;13:136.","DOI":"10.1186\/1471-2407-13-136"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"Javle MM, Shroff RT, Xiong H, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.\n                      BMC Cancer\n                      . 2010;10:368.","DOI":"10.1186\/1471-2407-10-368"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"Yeo W, Chan SL, Mo FK, et al. Phase I\/II study of temsirolimus for patients with unresectable hepatocellular carcinoma (HCC) - a correlative study to explore potential biomarkers for response.\n                      BMC Cancer\n                      . 2015;15:395.","DOI":"10.1186\/s12885-015-1334-6"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Fructuoso AI, Sant\u00edn Cantero JM, P\u00e9rez Flores I, et al. Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen.\n                      Transplant Proc\n                      . 2010;42:3047\u20139.","DOI":"10.1016\/j.transproceed.2010.07.081"},{"key":"ref137","doi-asserted-by":"crossref","unstructured":"Zhu AX, Abrams TA, Miksad R, et al. Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma.\n                      Cancer\n                      . 2011;117:5094\u2013102.","DOI":"10.1002\/cncr.26165"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Lv C-L, Li J. Bortezomib as a probable cause of the syndrome of inappropriate antidiuretic hormone secretion: A case report and review of the literature.\n                      Mol Clin Oncol\n                      . 2017;7:667\u201372.","DOI":"10.3892\/mco.2017.1366"},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"Schelman WR, Traynor AM, Holen KD, et al. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.\n                      Invest New Drugs\n                      . 2013;31:1539\u201346.","DOI":"10.1007\/s10637-013-0029-6"},{"key":"ref140","doi-asserted-by":"crossref","unstructured":"Holkova B, Kmieciak M, Bose P, et al. Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.\n                      Leuk Lymphoma\n                      . 2016;57:635\u201343.","DOI":"10.3109\/10428194.2015.1075019"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.\n                      Blood\n                      . 2018;131:397\u2013407.","DOI":"10.1182\/blood-2017-09-806737"},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.\n                      Blood\n                      . 2011;117:5827\u201334.","DOI":"10.1182\/blood-2010-10-312603"},{"key":"ref143","doi-asserted-by":"crossref","unstructured":"Gimsing P, Hansen M, Knudsen LM, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.\n                      Eur J Haematol\n                      . 2008;81:170\u20136.","DOI":"10.1111\/j.1600-0609.2008.01102.x"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.\n                      J Thorac Oncol\n                      . 2009;4:97\u2013101.","DOI":"10.1097\/JTO.0b013e318191520c"},{"key":"ref145","doi-asserted-by":"crossref","unstructured":"Guerra Y, Lacuesta E, Marquez F, et al. Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.\n                      Pituitary\n                      . 2010;13:54\u20139.","DOI":"10.1007\/s11102-009-0202-2"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"Huang T-Y, Lin J-P, Lieu A-S, et al. Pituitary apoplexy induced by gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.\n                      World J Surg Oncol\n                      . 2013;11:254.","DOI":"10.1186\/1477-7819-11-254"},{"key":"ref147","doi-asserted-by":"crossref","unstructured":"Engel G, Huston M, Oshima S, et al. Pituitary apoplexy after leuprolide injection for ovum donation.\n                      J Adolesc Health\n                      . 2003;32:89\u201393.","DOI":"10.1016\/S1054-139X(02)00372-5"},{"key":"ref148","doi-asserted-by":"crossref","unstructured":"Randeva HS, Schoebel J, Byrne J, et al. Classical pituitary apoplexy: clinical features, management and outcome.\n                      Clin Endocrinol (Oxf)\n                      . 1999;51:181\u20138.","DOI":"10.1046\/j.1365-2265.1999.00754.x"},{"key":"ref149","doi-asserted-by":"crossref","unstructured":"Karahan S, Karagoz H, Erden A, et al. Codeine-induced syndrome of inappropriate antidiuretic hormone: case report.\n                      Balk Med J\n                      . 2014;33:107\u20139.","DOI":"10.5152\/balkanmedj.2013.9424"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"Day L, Kleinschmidt K, Forrester MB, Feng S-Y. Comparison of unintentional exposures to codeine and hydrocodone reported to Texas poison centers.\n                      J Emerg Med\n                      . 2016;50:744\u201352.","DOI":"10.1016\/j.jemermed.2016.01.023"},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"Nagatomo I, Katafuchi T, Koizumi K. Effects of the opiates on the paraventricular nucleus in genetically polydipsic mice.\n                      Brain Res\n                      . 1992;598:23\u201332.","DOI":"10.1016\/0006-8993(92)90163-4"},{"key":"ref152","doi-asserted-by":"crossref","unstructured":"Kramer HJ, Gl\u00e4nzer K, D\u00fcsing R. Role of prostaglandins in the regulation of renal water excretion.\n                      Kidney Int\n                      . 1981;19:851\u20139.","DOI":"10.1038\/ki.1981.89"},{"key":"ref153","doi-asserted-by":"crossref","unstructured":"Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP.\n                      Pharmacopsychiatry\n                      . 2004;37(Suppl. 1):S39\u201345.","DOI":"10.1055\/s-2004-815509"},{"key":"ref154","doi-asserted-by":"crossref","unstructured":"Shepshelovich D, Schechter A, Calvarysky B, et al. Medication-induced SIADH: distribution and characterization according to medication class: Medication-induced SIADH characterization.\n                      Br J Clin Pharmacol\n                      . 2017;83:1801\u20137.","DOI":"10.1111\/bcp.13256"},{"key":"ref155","doi-asserted-by":"crossref","unstructured":"Wilton LV, Shakir S. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.\n                      Epilepsia\n                      . 2002;43:983\u201392.","DOI":"10.1046\/j.1528-1157.2002.01702.x"},{"key":"ref156","doi-asserted-by":"crossref","unstructured":"Kaeley N, Kabi A, Bhatia R, Mohanty A. Carbamazepine-induced hyponatremia - A wakeup call.\n                      J Fam Med Prim Care\n                      . 2019;8:1786\u20138.","DOI":"10.4103\/jfmpc.jfmpc_185_19"},{"key":"ref157","doi-asserted-by":"crossref","unstructured":"Buon M, Gaillard C, Martin J, et al. Risk of proton pump inhibitor-induced mild hyponatremia in older adults.\n                      J Am Geriatr Soc\n                      . 2013;61:2052\u20134.","DOI":"10.1111\/jgs.12534"},{"key":"ref158","doi-asserted-by":"crossref","unstructured":"Ferreira F, Mateus S, Santos AR, et al. Pantoprazole-related symptomatic hyponatremia.\n                      Eur J Case Rep Intern Med\n                      . 2016;3:000341.","DOI":"10.12890\/2015_000341"},{"key":"ref159","doi-asserted-by":"crossref","unstructured":"Shafi Kuchay M. Acute severe diarrhoea and hyponatremia after zoledronic acid infusion: an acute phase reaction.\n                      Clin Cases Miner Bone Metab\n                      . 2017;14:101.","DOI":"10.11138\/ccmbm\/2017.14.1.101"},{"key":"ref160","doi-asserted-by":"crossref","unstructured":"Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone.\n                      Am J Med\n                      . 1967;42:790\u2013806.","DOI":"10.1016\/0002-9343(67)90096-4"},{"key":"ref161","doi-asserted-by":"crossref","unstructured":"Ellison DH, Berl T. The syndrome of inappropriate antidiuresis.\n                      N Engl J Med\n                      . 2007;356:2064\u201372.","DOI":"10.1056\/NEJMcp066837"},{"key":"ref162","doi-asserted-by":"crossref","unstructured":"Grant P, Ayuk J, Bouloux P-M, et al. The diagnosis and management of inpatient hyponatraemia and SIADH.\n                      Eur J Clin Invest\n                      . 2015;45:888\u201394.","DOI":"10.1111\/eci.12465"},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"Berardi R, Antonuzzo A, Blasi L, et al. Practical issues for the management of hyponatremia in oncology.\n                      Endocrine\n                      . 2018;61:158\u201364.","DOI":"10.1007\/s12020-018-1547-y"},{"key":"ref164","doi-asserted-by":"crossref","unstructured":"Gross P. Clinical management of SIADH.\n                      Ther Adv Endocrinol Metab\n                      . 2012;3:61\u201373.","DOI":"10.1177\/2042018812437561"},{"key":"ref165","doi-asserted-by":"crossref","unstructured":"Elazzazy S, Mohamed AE, Gulied A. Cyclophosphamide-induced symptomatic hyponatremia, a rare but severe side effect: a case report.\n                      Onco Targets Ther\n                      . 2014;7:1641\u20135.","DOI":"10.2147\/OTT.S66350"},{"key":"ref166","doi-asserted-by":"crossref","unstructured":"Sterns RH. Treatment of severe hyponatremia.\n                      Clin J Am Soc Nephrol\n                      . 2018;13:641\u20139.","DOI":"10.2215\/CJN.10440917"},{"key":"ref167","doi-asserted-by":"crossref","unstructured":"Lasheen I, Doi SAR, Al-Shoumer KAS. Glucocorticoid replacement in panhypopituitarism complicated by myelinolysis.\n                      Med Princ Pract\n                      . 2005;14:115\u20137.","DOI":"10.1159\/000083923"},{"key":"ref168","unstructured":"Lee W-C, Cheng Y-F, Chen J-B. Treating hyponatremia in an empty sella syndrome patient complicated with possible myelinolysis.\n                      Chang Gung Med J\n                      . 2002;25:838\u201343."},{"key":"ref169","doi-asserted-by":"crossref","unstructured":"Yoshioka K, Minami M, Fujimoto S, et al. Incremental increases in glucocorticoid doses may reduce the risk of osmotic demyelination syndrome in a patient with hyponatremia due to central adrenal insufficiency.\n                      Intern Med Tokyo Jpn\n                      . 2012;51:1069\u201372.","DOI":"10.2169\/internalmedicine.51.6507"},{"key":"ref170","doi-asserted-by":"crossref","unstructured":"Muhsin SA, Mount DB. Diagnosis and treatment of hypernatraemia.\n                      Best Pract Res Clin Endocrinol Metab\n                      . 2016;30:189\u2013203.","DOI":"10.1016\/j.beem.2016.02.014"}],"container-title":["European Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/endocrine-oncology\/journal-articles\/anticancer-medications-and-sodium-dysmetabolism\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:59:48Z","timestamp":1764745188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchendocrinology.com\/endocrine-oncology\/journal-articles\/anticancer-medications-and-sodium-dysmetabolism\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":170,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["EE.2020.16.2.122"],"URL":"https:\/\/doi.org\/10.17925\/ee.2020.16.2.122","relation":{},"ISSN":["1758-3772"],"issn-type":[{"value":"1758-3772","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}